Lilly has a long history of developing and manufacturing insulin, having introduced the world’s first commercial insulin 94 years ago.

Lilly became the first company to manufacture this life-saving medicine on a large scale – making it widely available to people who so desperately needed it

Lilly became the first company to manufacture this life-saving medicine on a large scale – making it widely available to people who so desperately needed it.

In 1982, Lilly introduced another milestone in diabetes research: The first biosynthetic ‘human’ insulin with recombinant DNA technology. And in 1996, Lilly led again in innovation with the first rapid-acting insulin analog. Lilly continues to build upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio, Lilly is working towards advancing their understanding of insulin.

Comprehensive insulin portfolio

Basaglar is a new basal insulin glargine in Lilly’s insulin portfolio, providing an option for patients with diabetes who need a long-acting solution. The biosimilar, insulin glargine is an injectable, prescription medicine designed to be taken at the same time daily to lower blood glucose.* Basaglar provides an option for patients with diabetes who need a long-acting solution. Humalog®, Lilly’s rapid-acting insulin analog, indicated to improve glycaemic control in adults and children, provides an option for doctors to intensify treatment with Basalgar if and when required. Together, Basaglar and Humalog represent an efficacious, well-reimbursed and thoroughly supported basal bolus treatment option for patients living with diabetes. Lilly offers further options through Humalog Mix25 and Humalog Mix50. Almost all plans under Discovery Health require no additional copayments for either Basaglar or the entire Humalog portfolio.

Biosimilars represent an important opportunity for physicians, patients and healthcare systems to positively impact on the treatment and management of diabetes with a comprehensive insulin portfolio. The ‘Standards Of Medical Care In Diabetes 2017’ issued by the American Diabetes Association has added a section describing the role of newly available biosimilar insulins in diabetes care and specifically references Basaglar. It further goes on to mention the importance of addressing the cost-effectiveness of different therapies, and the fact that Basaglar has been approved, “Through an abbreviated FDA approval pathway based, in part, on the FDA’s finding of safety and effectiveness for the reference U-100 glargine product.”

Initiate patients with an optimal solution

Cost is an important consideration in light of diabetes treatment being a lifelong journey, often complicated by other concomitant conditions that compound the ongoing costs of treating diabetes. Managing these costs is important to allow patients to adhere to their insulin regimen while minimising out-of-pocket expenses. Basaglar represents significant financial relief to patients with diabetes. For patients on medical aid, treatment costs are likely to be fully covered, while for the uninsured or underinsured, Basaglar comes at a price of up to 30% less than current market alternatives, whilst still providing the same level of efficacy and quality. Almost all plans under Discovery Health require no additional co-payments for either Basaglar the entire Humalog portfolio.